) Resolved propose to the Annual Ordinary General Meeting of Shareholders to consider and approve the Balance Sheet and Profit and Loss Statement of the Company for the fiscal year ended December 31, 2017
will be made on May 24, 2019. The mentioned right will be further approved by the AGM 2019. 2. Approved to propose to the AGM to consider and approve the financial statement of the company for the fiscal
Consolidated Financial Results 1. Operating Results Revenues In the first half of fiscal year 2021, the total consolidated revenues were 10,386 million baht, decreasing of 655 million baht or 6% y-y. In the
1st quarter financial statements as of May 31, 2022 which were reviewed by Deloitte Touche Tohmatsu Jaiyos Audit Company Limited. The operating performance is summarized are as follows. Overview
the consolidated reviewed the 3rd quarter financial statements as of November 30, 2022 which were reviewed by Deloitte Touche Tohmatsu Jaiyos Audit Company Limited. The operating performance is
, public spending and tourism sector still expanded which resulted from low base in the previous year. (Source: BOT Press Release No.64/2019 on the Economic and Monetary Conditions for September and the
ทางการเงิน (financial highlight) จากงบการเงินหรืองบการเงินรวม ของผู้รับประกันรายได้ประจำงวดปีบัญชี 3 ปีล่าสุด หรือเท่าที่มีการดำเนินการ ꃂ 숀 ꃂ⠀Ȁ⤎ Ѐ✎㈎ℎ䀎⬎䜎ᤎȎⴎᨎ⌎㐎⤎ㄎᜎࠎㄎᐎĎ㈎⌎ࠎ㈎ĎĎ㈎⌎✎㐎䀎Ў⌎㈎『⬎䰎䄎┎『ᬎ⌎『䀎
encumbrances as shown in the Audited Consolidated Financial Statements for the fiscal year ended 31 December 2018 as follows: – Capital commitments in the total of THB 1,545.9 million. – Future minimum lease
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like